^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDK4 amplification

    i
    Entrez ID:
    1019
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma (NCT06025747)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/09/2025
    Primary completion :
    03/03/2025
    Completion :
    03/03/2026
    MDM2 • CDK4
    |
    CDK4 amplification
    |
    Verzenio (abemaciclib)
    Palbociclib and Pembrolizumab in Central Nervous System Metastases (NCT02896335)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/02/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3
    |
    CCNE1 amplification • CCND1 amplification • CDK4 amplification
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib)
    A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (NCT03834740)
    Phase 1
    St. Joseph's Hospital and Medical Center, Phoenix
    Completed
    Last update posted :
    05/10/2024
    Initiation :
    12/21/2018
    Primary completion :
    02/18/2022
    Completion :
    02/18/2022
    PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B
    |
    PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression
    |
    everolimus • Kisqali (ribociclib)
    Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 (NCT04074785)
    Phase 1
    University of Texas Southwestern Medical Center
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    12/13/2019
    Primary completion :
    10/24/2024
    Completion :
    10/24/2025
    CDKN2A • RB1 • CDK4 • CDKN2B
    |
    CDK4 amplification
    |
    Avastin (bevacizumab) • Verzenio (abemaciclib)
    LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (NCT04391595)
    Phase 1
    Nader Sanai
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    07/08/2020
    Primary completion :
    12/01/2024
    Completion :
    02/01/2025
    CDKN2A • CDK4 • CDKN2B
    |
    CDK4 amplification
    |
    Verzenio (abemaciclib) • temuterkib (LY3214996)
    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 (NCT03310879)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    11/21/2017
    Primary completion :
    12/31/2024
    Completion :
    04/30/2025
    CCND1 • CDK4 • CDK6
    |
    CCND1 amplification • CDK4 amplification • CCND1 mutation
    |
    Verzenio (abemaciclib)
    CDK4/6 Tumor, Abemaciclib, Paclitaxel (NCT04594005)
    Phase 1/2
    Yonsei University
    Active, not recruiting
    Last update posted :
    10/06/2023
    Initiation :
    02/25/2021
    Primary completion :
    08/10/2024
    Completion :
    08/10/2024
    CCND1 • CDK4 • CDK6
    |
    CCND1 amplification • CDK4 amplification • CCND1 mutation
    |
    paclitaxel • Verzenio (abemaciclib)
    A Study of Abemaciclib in Recurrent Glioblastoma (NCT02981940)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    07/27/2023
    Initiation :
    02/09/2017
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    CDKN2A • RB1 • CDK4 • CDKN2B • CDK6
    |
    CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type
    |
    Verzenio (abemaciclib)
    Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) (NCT03356223)
    Phase 2
    Centre Leon Berard
    Completed
    Last update posted :
    02/23/2023
    Initiation :
    02/05/2018
    Primary completion :
    11/05/2022
    Completion :
    12/05/2022
    CDKN2A • CCND1
    |
    CDKN2A deletion • CCND1 amplification • CDK4 amplification
    |
    Erbitux (cetuximab) • Verzenio (abemaciclib)
    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790)
    Phase 2
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    03/11/2021
    Initiation :
    10/01/2009
    Primary completion :
    10/01/2019
    Completion :
    10/01/2019
    HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2
    |
    KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation
    |
    cisplatin • Ibrance (palbociclib)
    ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas (NCT02264613)
    Phase 1/2
    Aileron Therapeutics, Inc.
    Completed
    Last update posted :
    07/14/2020
    Initiation :
    10/01/2014
    Primary completion :
    03/01/2020
    Completion :
    04/01/2020
    TP53 • MDM2 • CDK4
    |
    TP53 wild-type • MDM2 amplification • CDK4 amplification
    |
    ALRN-6924
    LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) (NCT02187783)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    07/18/2019
    Initiation :
    08/25/2014
    Primary completion :
    01/17/2018
    Completion :
    01/17/2018
    CDKN2A • CCND1 • CDK4 • CDK6 • CCND3
    |
    CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification
    |
    Kisqali (ribociclib)
    Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations (NCT03454919)
    Phase 2
    Peking University Cancer Hospital & Institute
    Unknown status
    Last update posted :
    03/06/2018
    Initiation :
    03/30/2018
    Primary completion :
    12/31/2019
    Completion :
    06/30/2020
    CDKN2A • CCND1 • CDK4
    |
    CCND1 amplification • CDK4 amplification
    |
    Ibrance (palbociclib)
    PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (NCT01209598)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/06/2017
    Initiation :
    09/23/2010
    Primary completion :
    10/25/2016
    Completion :
    10/25/2016
    CDK4
    |
    CDK4 amplification
    |
    Ibrance (palbociclib)
    A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients (NCT02671513)
    Phase 1
    Jiangsu HengRui Medicine Co., Ltd.
    Unknown status
    Last update posted :
    04/12/2016
    Initiation :
    01/01/2016
    Primary completion :
    11/01/2016
    Completion :
    04/01/2017
    CDKN2A • CCND1 • CDK4
    |
    CDK4 amplification
    |
    AiRuiKang (dalpiciclib)